Anti-Insulin-like Growth Factor I Antibodies Affect Locomotion and Passive Avoidance Performances in Sprague-Dawley Rats
Insulin-like growth factor I (IGF-I) is a protein implicated in the regulation of several growth processes. Specifically, IGF-I mediates the action of growth hormone (GH) on its target organs and regulates both the release of somatostatin and GH from the hypothalamus and the release of GH and prolactin from the pituitary gland . Moreover, it exerts a tissue-specific autocrine and paracrine role during the course of normal growth and differentiation . IGF-I also plays a physiological role in the central nervous system (CNS) both during early development and adulthood [3-5]. Alteration in the level of IGF-I during early postnatal life is correlated with several brain dysfunctions . IGF-I appears to participate in normal CNS development by regulating neuronal survival and differentiation and by stimulating glial growth ; postnatal synthesis of IGF-I has been detected in brain regions characterised by life-long processes of synapse formation, suggesting an additional role for this peptide in promoting and maintaining neuronal plasticity. Moreover, transgenic mice overexpressing IGF-I have significantly larger brains than controls, likely a result of increased cell size and number , while homozygous IGF-I (-/-) mice show reduced brain weights at 2 months of age .
KeywordsPassive Avoidance Passive Avoidance Task Ultrasonic Vocalization Open Field Arena Passive Avoidance Performance
Unable to display preview. Download preview PDF.
- 1.Berelowitz M, Szabo M, Frohman LA, Firestone S, Chu L, Hintz RL (1981) Somatomedin - C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary Science 212: 1279–1281Google Scholar
- 8.Beck KD, Powell-Braxton L, Widmer HR, Valverde J, Hefti F (1995) Igfl gene disruption results in reduced brain size, CNS hypomyelination, and loss of hippocampal granule and striatal parvalbumin-containing neurons. Neuron 14: 717–730Google Scholar
- 11.Calamandrei G, Alleva E (in press) Growth factors in neurobehavioral development. In: Cosmi EV, Di Renzo GC, Hawkins DH (eds) Recent advances in perinatal medicine. Academic Publishers, LondonGoogle Scholar
- 18.Chiarotti F, Alleva E, Bignami G (1987) Problems of test choice and data analysis in behavioral teratology: The case of prenatal benzodiazepines. Neurotoxicol Teratol 9: 179–186Google Scholar
- 19.Knusel B, Michel PP, Schwaber JS, Hefti F (1990) Selective and nonselective stimulation of central cholinergic and dopaminergic development in vitro by nerve growth factor, basic fibroblast growth factor, epidermal growth factor, insulin and the insulin-like growth factors I and II. J Neurosci 10: 558–570PubMedGoogle Scholar
- 21.Holtzman DM, Santucci D, Kilbridge J, Couzens JC, Fontana DJ, Daniels SE, Johnson RM, Chen K, Sun Y, Carlson E, Alleva E, Epstein CJ, Mobley WC (1996) Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc Natl Acad Sci USA 93: 13333–13338PubMedCrossRefGoogle Scholar
- 22.Ricceri L, Calamandrei G, Berger-Sweeney J (1997) Different effects of postnatal day 1 vs 7 192 IgG sapor in lesions on learning, exploratory behavior and neurochemistry in juvenile rats. Behav Neurosci (in press)Google Scholar
- 23.Everitt BJ, Robbins TW, (1997) Central cholinergic systems and cognition. Annu Rev Psychol 48:649–684Google Scholar